Humanigen, Inc. (NASDAQ:HGEN – Get Rating) has received a consensus recommendation of “Hold” from the eight research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $24.75.
Separately, Zacks Investment Research downgraded Humanigen from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.
Shares of HGEN opened at $2.18 on Wednesday. The firm has a market cap of $153.98 million, a PE ratio of -0.69 and a beta of -1.01. The firm’s 50 day moving average price is $2.38 and its 200 day moving average price is $3.14. Humanigen has a twelve month low of $1.67 and a twelve month high of $22.37.
In related news, insider Dale Chappell acquired 173,700 shares of the stock in a transaction dated Wednesday, May 18th. The shares were acquired at an average price of $1.96 per share, for a total transaction of $340,452.00. Following the completion of the purchase, the insider now owns 8,066,575 shares in the company, valued at approximately $15,810,487. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders bought 1,726,188 shares of company stock worth $4,574,600. 21.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Citigroup Inc. lifted its position in Humanigen by 52.3% in the third quarter. Citigroup Inc. now owns 286,223 shares of the company’s stock worth $1,697,000 after purchasing an additional 98,273 shares during the period. Voloridge Investment Management LLC bought a new position in Humanigen in the third quarter worth $3,121,000. Pinnacle Associates Ltd. bought a new position in Humanigen in the fourth quarter worth $39,000. UBS Asset Management Americas Inc. lifted its position in Humanigen by 18.8% in the third quarter. UBS Asset Management Americas Inc. now owns 25,364 shares of the company’s stock worth $150,000 after purchasing an additional 4,017 shares during the period. Finally, Murchinson Ltd. lifted its position in Humanigen by 350.0% in the fourth quarter. Murchinson Ltd. now owns 4,500,000 shares of the company’s stock worth $16,763,000 after purchasing an additional 3,500,000 shares during the period. Institutional investors and hedge funds own 64.34% of the company’s stock.
About Humanigen (Get Rating)
Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.
- Get a free copy of the StockNews.com research report on Humanigen (HGEN)
- 3 Outperforming Energy Stocks with More in the Tank
- American Well Corporation Stock May Well Be Bottoming
- There Are Cracks In The Paint At Sherwin-Williams
- Three Beaten Down Stocks The Insiders Are Buying
- Should Medtronic Make the Cut For Your Recovery Watchlist?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.